Aeglea BioTherapeutics Inc. | Mutual Funds
Mutual Funds that own Aeglea BioTherapeutics Inc.
Prudential Jennison Health Sciences Fund
602,772
2.74%
0
0.26%
07/31/2018
Vanguard Total Stock Market Index Fund
452,174
2.06%
41,422
0%
07/31/2018
iShares Russell 2000 ETF
341,106
1.55%
-183
0.01%
09/06/2018
Vanguard Extended Market Index Fund
187,539
0.85%
3,700
0%
07/31/2018
iShares Russell 2000 Growth ETF
167,825
0.76%
0
0.02%
09/06/2018
Bridgeway Ultra Small Company Market Fund
75,000
0.34%
0
0.19%
12/31/2017
APO Medical Opportunities
65,444
0.3%
65,444
0.13%
03/31/2018
Fidelity Spartan Extended Market Index Fund
61,972
0.28%
0
0%
07/31/2018
iShares Micro Cap ETF
43,677
0.2%
0
0.04%
09/06/2018
Schwab Small Cap Index Fund
30,300
0.14%
30,300
0.01%
06/30/2018
| Address |
Barton Oaks Plaza One
Austin Texas 78746
United States
|
|
Employees
|
- |
| Website |
http://www.aegleabio.com |
| Updated |
07/08/2019 |
| Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. The company was founded by George Georgiou and David G. |
